Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.

Montecucco F, Di Marzo V.

Trends Pharmacol Sci. 2012 Jun;33(6):331-40. doi: 10.1016/j.tips.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503477
2.

Gut feelings about the endocannabinoid system.

Di Marzo V, Piscitelli F.

Neurogastroenterol Motil. 2011 May;23(5):391-8. doi: 10.1111/j.1365-2982.2011.01689.x.

PMID:
21481098
3.

Endocannabinoids and the Cardiovascular System in Health and Disease.

O'Sullivan SE.

Handb Exp Pharmacol. 2015;231:393-422. doi: 10.1007/978-3-319-20825-1_14. Review.

PMID:
26408169
4.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

5.

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

Petrosino S, Di Marzo V.

Curr Opin Investig Drugs. 2010 Jan;11(1):51-62. Review.

PMID:
20047159
6.

Cannabinoids and the skeleton: from marijuana to reversal of bone loss.

Bab I, Zimmer A, Melamed E.

Ann Med. 2009;41(8):560-7. doi: 10.1080/07853890903121025. Review.

PMID:
19634029
7.

Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.

Papahatjis DP, Nahmias VR, Andreou T, Fan P, Makriyannis A.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1616-20. Epub 2006 Jan 4.

PMID:
16387492
8.

Role of endocannabinoids in cardiovascular shock.

Malinowska B, Lupinski S, Godlewski G, Baranowska U, Schlicker E.

J Physiol Pharmacol. 2008 Dec;59 Suppl 8:91-107. Review.

PMID:
19258666
9.

The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism?

Steffens S, Pacher P.

Curr Drug Targets. 2015;16(4):334-41. Review.

PMID:
25469884
10.

Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.

Braun A, Engel T, Aguilar-Pimentel JA, Zimmer A, Jakob T, Behrendt H, Mempel M.

Immunobiology. 2011 Apr;216(4):466-76. doi: 10.1016/j.imbio.2010.09.004. Epub 2010 Sep 18.

PMID:
21056512
11.

Dissecting the cannabinergic control of behavior: The where matters.

Busquets-Garcia A, Desprez T, Metna-Laurent M, Bellocchio L, Marsicano G, Soria-Gomez E.

Bioessays. 2015 Nov;37(11):1215-25. doi: 10.1002/bies.201500046. Epub 2015 Aug 11. Review.

PMID:
26260530
12.

Pharmacology of cannabinoids.

Grotenhermen F.

Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):14-23. Review.

PMID:
15159677
13.

Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.

Takeda S, Yamaori S, Motoya E, Matsunaga T, Kimura T, Yamamoto I, Watanabe K.

Toxicology. 2008 Mar 12;245(1-2):141-6. doi: 10.1016/j.tox.2007.12.019. Epub 2007 Dec 28.

PMID:
18249480
14.

The endocannabinoid system in Huntington's disease.

Pazos MR, Sagredo O, Fernández-Ruiz J.

Curr Pharm Des. 2008;14(23):2317-25. Review.

PMID:
18781982
15.

Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.

Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M.

Brain Res. 2008 Jan 10;1188:157-64. Epub 2007 Oct 12.

PMID:
18021759
16.

Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Springs AE, Karmaus PW, Crawford RB, Kaplan BL, Kaminski NE.

J Leukoc Biol. 2008 Dec;84(6):1574-84. doi: 10.1189/jlb.0508282. Epub 2008 Sep 12.

17.

Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

De Petrocellis L, Di Marzo V.

J Neuroimmune Pharmacol. 2010 Mar;5(1):103-21. doi: 10.1007/s11481-009-9177-z. Epub 2009 Oct 22. Review.

PMID:
19847654
18.

Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.

Basavarajappa BS, Hungund BL.

Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):287-99. Review.

PMID:
12052043
19.

The role of the endocannabinoid system in atherosclerosis.

Mach F, Steffens S.

J Neuroendocrinol. 2008 May;20 Suppl 1:53-7. doi: 10.1111/j.1365-2826.2008.01685.x. Review.

PMID:
18426500
20.

Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Mendizábal VE, Adler-Graschinsky E.

Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23.

Supplemental Content

Support Center